Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022
December 01 2022 - 4:05PM
Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that progress with
CC-42344 for the treatment of pandemic and seasonal influenza A
from its Phase 1 study was presented today at the World Antiviral
Congress 2022 underway in San Diego. The presentation, “Novel
Broad-Spectrum Influenza A PB2 Inhibitor: Clinical Update,” was
delivered by Cocrystal President and co-interim CEO Sam Lee, PhD
and the slides are available here.
“We appreciate the opportunity to present our
antiviral drug discovery platform technology and favorable interim
Phase 1 data,” said Dr. Lee. “Seasonal and pandemic influenza A
continue to be major global health threats, especially given the
potential for resistance against approved antivirals. Our
presentation highlights potential clinical benefits for the
treatment of pandemic influenza and the advantages of the oral
influenza antiviral CC-42344 drug, which targets the PB2 protein of
the influenza polymerase complex. We believe this novel mechanism
of action holds promise against all significant influenza A strains
including bird flu, while also having a high barrier to resistance.
Our assessment to date also indicates that CC-42344 will have a
strong synergistic effect when used with approved antivirals.”
In November 2022 Cocrystal reported that orally
administered CC-42344 showed a favorable safety profile in both the
single- and multiple-ascending dose portions of the Phase 1 study.
The Company is currently awaiting pharmacokinetic results from this
study and plans to report topline results later this year.
About
CC-42344CC-42344 is a novel PB2 inhibitor
discovered using Cocrystal’s proprietary structure-based drug
discovery platform technology. CC-42344 targets the influenza
polymerase, an essential replication enzyme with several highly
conserved regions common to multiple influenza strains. In vitro
testing showed CC-42344’s excellent antiviral activity against
influenza A strains, including pandemic and seasonal strains, as
well as against strains resistant to Tamiflu® and Xofluza®.
About Cocrystal Pharma,
Inc.Cocrystal Pharma, Inc. is a clinical-stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication process of influenza
viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses
and noroviruses. Cocrystal employs unique structure-based
technologies and Nobel Prize-winning expertise to create first- and
best-in-class antiviral drugs. For further information about
Cocrystal, please visit www.cocrystalpharma.com.
Cautionary Note Regarding
Forward-Looking StatementsThis press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
regarding the potential clinical benefits of CC-42344, including
its prospective efficacy against all influenza A strains, high
barrier to resistance and synergistic effects with approved
antivirals, and our plans to report topline results of the Phase 1
study by the end of 2022. The words "believe," "may," "estimate,"
"continue," "anticipate," "intend," "should," "plan," "could,"
"target," "potential," "is likely," "will," "expect" and similar
expressions, as they relate to us, are intended to identify
forward-looking statements. We have based these forward-looking
statements largely on our current expectations and projections
about future events. Some or all of the events anticipated by these
forward-looking statements may not occur. Important factors that
could cause actual results to differ from those in the
forward-looking statements include, but are not limited to, the
risks and uncertainties arising from any future impact of COVID-19
(including long-term or pervasive effects of the virus), inflation,
interest rate increases and the war in Ukraine on the U.K. and
global economy and on our Company, including supply chain
disruptions and our continued ability to proceed with our programs,
including our influenza A program, the ability of the contract
research organization to recruit patients into clinical trials, the
results of future preclinical and clinical studies, and general
risks arising from clinical trials. Further information on our risk
factors is contained in our filings with the SEC, including our
Annual Report on Form 10-K for the year ended December 31, 2021.
Any forward-looking statement made by us herein speaks only as of
the date on which it is made. Factors or events that could cause
our actual results to differ may emerge from time to time, and it
is not possible for us to predict all of them. We undertake no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future developments or
otherwise, except as may be required by law.
Investor Contact:LHA Investor
RelationsJody Cain310-691-7100jcain@lhai.com
Media Contact:JQA PartnersJules
Abraham917-885-7378Jabraham@jqapartners.com
+# # #
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Sep 2023 to Sep 2024